Title
Latin American consensus on the supportive management of patients with severe combined immunodeficiency
Date Issued
01 October 2019
Access level
open access
Resource Type
journal article
Author(s)
Bustamante Ogando J.C.
Partida Gaytán A.
Álvarez Cardona A.
Bezrodnik L.
Borzutzky A.
Blancas Galicia L.
Cabanillas D.
Condino-Neto A.
De Colsa Ranero A.
Espinosa Padilla S.
Fernandes J.F.
García Campos J.A.
Gómez Tello H.
González Serrano M.E.
Gutiérrez Hernández A.
Hernández Bautista V.M.
Ivankovich Escoto G.
King A.
Lessa Mazzucchelli J.
Llamas Guillén B.A.
Lugo Reyes S.O.
Moreno Espinosa S.
Oleastro M.
Otero Mendoza F.
Poli Harlowe M.C.
Porras O.
Ramirez Uribe N.
Regairaz L.
Rivas Larrauri F.
Saracho Weber F.J.
Grumach A.S.
Staines Boone T.
Tavares Costa-Carvalho B.
Yamazaki Nakashimada M.A.
Espinosa Rosales F.J.
Publisher(s)
Mosby Inc.
Abstract
Severe combined immunodeficiency (SCID) represents the most lethal form of primary immunodeficiency, with mortality rates of greater than 90% within the first year of life without treatment. Hematopoietic stem cell transplantation and gene therapy are the only curative treatments available, and the best-known prognostic factors for success are age at diagnosis, age at hematopoietic stem cell transplantation, and the comorbidities that develop in between. There are no evidence-based guidelines for standardized clinical care for patients with SCID during the time between diagnosis and definitive treatment, and we aim to generate a consensus management strategy on the supportive care of patients with SCID. First, we gathered available information about SCID diagnostic and therapeutic guidelines, then we developed a document including diagnostic and therapeutic interventions, and finally we submitted the interventions for expert consensus through a modified Delphi technique. Interventions are grouped in 10 topic domains, including 123 “agreed” and 38 “nonagreed” statements. This document intends to standardize supportive clinical care of patients with SCID from diagnosis to definitive treatment, reduce disease burden, and ultimately improve prognosis, particularly in countries where newborn screening for SCID is not universally available and delayed diagnosis is the rule. Our work intends to provide a tool not only for immunologists but also for primary care physicians and other specialists involved in the care of patients with SCID.
Start page
897
End page
905
Volume
144
Issue
4
Language
English
OCDE Knowledge area
Inmunología
Subjects
Scopus EID
2-s2.0-85071427598
PubMed ID
Source
Journal of Allergy and Clinical Immunology
ISSN of the container
00916749
Sponsor(s)
This work was partially funded by Fundación Mexicana para Niñas y Niños con Inmunodeficiencias Primarias (FUMENI).
This work was partially funded by Fundaci?n Mexicana para Ni?as y Ni?os con Inmunodeficiencias Primarias (FUMENI).
Sources of information:
Directorio de Producción Científica
Scopus